Elevation Oncology Inc (ELEV) - Net Assets
Based on the latest financial reports, Elevation Oncology Inc (ELEV) has net assets worth $46.73 Million USD as of March 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($82.22 Million) and total liabilities ($35.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Elevation Oncology Inc to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $46.73 Million |
| % of Total Assets | 56.84% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 35.74 |
Elevation Oncology Inc - Net Assets Trend (2019–2024)
This chart illustrates how Elevation Oncology Inc's net assets have evolved over time, based on quarterly financial data. Also explore ELEV asset base for the complete picture of this company's asset base.
Annual Net Assets for Elevation Oncology Inc (2019–2024)
The table below shows the annual net assets of Elevation Oncology Inc from 2019 to 2024. For live valuation and market cap data, see Elevation Oncology Inc (ELEV) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $60.02 Million | +9.52% |
| 2023-12-31 | $54.81 Million | +11.78% |
| 2022-12-31 | $49.03 Million | -65.15% |
| 2021-12-31 | $140.70 Million | +709.58% |
| 2020-12-31 | $-23.08 Million | -293.00% |
| 2019-12-31 | $-5.87 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Elevation Oncology Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 23457300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.00K | 0.01% |
| Other Comprehensive Income | $61.00K | 0.10% |
| Other Components | $300.41 Million | 500.48% |
| Total Equity | $60.02 Million | 100.00% |
Elevation Oncology Inc Competitors by Market Cap
The table below lists competitors of Elevation Oncology Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Archtis Ltd
AU:AR9
|
$21.63 Million |
|
Zuleika Gold Ltd
AU:ZAG
|
$21.64 Million |
|
Puma Exploration Inc
V:PUMA
|
$21.65 Million |
|
Bcal Diagnostics Ltd
AU:BDX
|
$21.65 Million |
|
Gillanders Arbuthnot & Company Limited
NSE:GILLANDERS
|
$21.62 Million |
|
Rubean AG
F:R1B
|
$21.60 Million |
|
Adagio Medical Holdings, Inc Common Stock
NASDAQ:ADGM
|
$21.60 Million |
|
Nyesa Valores Corp SA
MC:NYE
|
$21.59 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Elevation Oncology Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 54,809,000 to 60,025,000, a change of 5,216,000 (9.5%).
- Net loss of 44,485,000 reduced equity.
- Share repurchases of 48,000 reduced equity.
- New share issuances of 44,207,000 increased equity.
- Other comprehensive income increased equity by 52,000.
- Other factors increased equity by 5,490,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-44.48 Million | -74.11% |
| Share Repurchases | $48.00K | -0.08% |
| Share Issuances | $44.21 Million | +73.65% |
| Other Comprehensive Income | $52.00K | +0.09% |
| Other Changes | $5.49 Million | +9.15% |
| Total Change | $- | 9.52% |
Book Value vs Market Value Analysis
This analysis compares Elevation Oncology Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.35x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.25 | $0.37 | x |
| 2020-12-31 | $-0.97 | $0.37 | x |
| 2021-12-31 | $6.06 | $0.37 | x |
| 2022-12-31 | $2.11 | $0.37 | x |
| 2023-12-31 | $1.61 | $0.37 | x |
| 2024-12-31 | $1.05 | $0.37 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Elevation Oncology Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -74.11%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.59x
- Recent ROE (-74.11%) is below the historical average (-62.36%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.29 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-14.96 Million |
| 2021 | -22.77% | 0.00% | 0.00x | 1.06x | $-46.11 Million |
| 2022 | -193.91% | 0.00% | 0.00x | 1.92x | $-99.98 Million |
| 2023 | -83.39% | 0.00% | 0.00x | 1.63x | $-51.18 Million |
| 2024 | -74.11% | 0.00% | 0.00x | 1.59x | $-50.49 Million |
Industry Comparison
This section compares Elevation Oncology Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Elevation Oncology Inc (ELEV) | $46.73 Million | 0.00% | 0.76x | $21.63 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Elevation Oncology Inc
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. It's lead candidate is EO-3021, an antibody-drug conjugate (ADC) comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 monoclonal antibody (mAb) site-specifically conjugated with a cleavable link… Read more